Disc Medicine, Inc. (IRON) shareholders
Close on Nov 17, 2026Market cap $2.94BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.10%) | 4,907,159 | 14.10% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (12.80%) | 4,875,473 | 12.80% | 13G (passive) amendment | Jun 30, 2026 |
| Ai Dmi LLC Joint filing with Access Industries Holdings LLC (8.00%), Access Industries Management, LLC (8.00%) and 1 more | 3,018,460 | 8.00% | 13D (active) amendment | Oct 20, 2025 |
| Len Blavatnik Joint filing with Ai Dmi LLC (6.60%), Access Industries Holdings LLC (6.60%) and 1 more | 2,943,410 | 6.60% | 13D (active) amendment | Oct 22, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (6.80%), Wellington Group Holdings LLP (6.80%) and 1 more | 2,343,499 | 6.40% | 13G (passive) | Mar 31, 2025 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (5.90%), Rajeev Shah (5.90%) and 1 more | 2,228,924 | 5.90% | 13G (passive) | Dec 30, 2025 |
| BlackRock, Inc. | 1,851,171 | 6.20% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IRON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,894,473 | 12.75% | $357.98M | −692,421 | 0.02% |
| BlackRock, Inc. | 2,467,899 | 6.43% | $180.50M | +194,068 | 0.00% |
| Ra Capital Management, L.P. | 2,450,221 | 6.38% | $179.21M | – | 1.56% |
| JPMorgan Chase & Co | 1,875,795 | 4.89% | $139.87M | +504,315 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,875,399 | 4.88% | $137.17M | +326,049 | 0.01% |
| Wellington Management Group Llp | 1,741,351 | 4.54% | $127.36M | +5,975 | 0.02% |
| State Street Corp | 1,648,836 | 4.29% | $120.60M | −49,408 | 0.00% |
| Vestal Point Capital, LP | 1,550,000 | 4.04% | $113.37M | +850,000 | 2.65% |
| Atlas Venture Life Science Advisors, LLC | 1,513,875 | 3.94% | $110.72M | – | 12.56% |
| Vanguard Capital Management LLC | 1,369,027 | 3.57% | $100.13M | −6,403 | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,354,852 | 3.53% | $99.09M | – | 2.16% |
| TCG Crossover Management, LLC | 1,341,862 | 3.50% | $98.14M | – | 2.36% |
| Bvf Inc/Il | 1,153,612 | 3.00% | $84.38M | −118,700 | 2.16% |
| Woodline Partners LP | 958,281 | 2.50% | $70.09M | – | 0.22% |
| Siren, L.L.C. | 888,401 | 2.31% | $64.98M | −100,000 | 1.31% |
| Logos Global Management LP | 875,000 | 2.28% | $64.00M | +315,000 | 2.76% |
| Opaleye Management Inc. | 855,000 | 2.23% | $62.53M | +434,000 | 5.66% |
| Geode Capital Management, LLC | 789,724 | 2.06% | $57.77M | +45,502 | 0.00% |
| Assenagon Asset Management S.A. | 768,316 | 2.00% | $56.19M | +222,069 | 0.04% |
| Deerfield Management Company, L.P. (Series C) | 657,000 | 1.71% | $48.05M | – | 0.50% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 216 | 43M | 100.0% | 39 / 77 | 62 / 22 | 5M | 3M |
| Q1 2026 | 203 | 42M | 100.0% | 47 / 81 | 44 / 38 | 9M | 4M |
| Q4 2025 | 197 | 38M | 99.7% | 42 / 86 | 48 / 11 | 8M | 5M |
| Q3 2025 | 168 | 35M | 91.1% | 26 / 62 | 44 / 9 | 5M | 5M |
| Q2 2025 | 151 | 34M | 88.8% | 26 / 68 | 37 / 31 | 4M | 3M |
| Q1 2025 | 157 | 33M | 86.4% | 27 / 74 | 31 / 21 | 9M | 2M |
| Q4 2024 | 152 | 27M | 69.2% | 37 / 49 | 45 / 15 | 4M | 5M |
| Q3 2024 | 132 | 27M | 71.6% | 25 / 58 | 28 / 12 | 4M | 3M |
| Q2 2024 | 121 | 29M | 74.7% | 29 / 55 | 30 / 37 | 10M | 4M |
| Q1 2024 | 130 | 23M | 59.1% | 31 / 58 | 28 / 12 | 4M | 2M |
| Q4 2023 | 112 | 20M | 52.9% | 32 / 40 | 29 / 10 | 4M | 4M |
| Q3 2023 | 91 | 20M | 51.9% | 19 / 39 | 19 / 18 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
218 funds held IRON in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IRON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,889,838 | 4.92% | $131.48M | 0.05% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 970,661 | 2.53% | $70.99M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 958,601 | 2.50% | $70.11M | 0.65% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 739,640 | 1.93% | $54.10M | 0.07% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 647,794 | 1.69% | $47.38M | 0.36% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 566,760 | 1.48% | $41.45M | 0.28% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 454,774 | 1.18% | $31.64M | 0.60% | May 31, 2026 |
| Select Health Care Portfolio | 450,000 | 1.17% | $31.31M | 0.54% | May 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 395,235 | 1.03% | $28.91M | 1.62% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 375,603 | 0.98% | $27.47M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 366,949 | 0.96% | $26.84M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 309,253 | 0.81% | $23.81M | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 278,384 | 0.73% | $21.44M | 0.24% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 274,234 | 0.71% | $20.06M | 0.77% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 261,158 | 0.68% | $19.10M | 0.12% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John D. Quisel | Chief Executive Officer, Director | 262,064 | 0.68% | Sep 16, 2026 |
| William Jacob Savage | Chief Medical Officer | 63,445 | 0.17% | Nov 12, 2026 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | 63,120 | 0.16% | Aug 26, 2026 |
| Rahul Khara | Chief Legal Officer | 57,324 | 0.15% | Aug 7, 2026 |
| Jean M. Franchi | Chief Financial Officer | 64,333 | 0.17% | Apr 15, 2026 |
| Pamela Stephenson | Chief Commercial Officer | 80,998 | 0.21% | Feb 17, 2026 |
| Kevin Bitterman | Director | 20,127 | 0.05% | Oct 21, 2026 |
| Georges Gemayel | Director | – | – | Jun 23, 2026 |
| Nadim Ahmed | Director | – | – | Jun 23, 2026 |
| Mark Chin | Director | – | – | Jun 23, 2026 |
| William Richard White | Director | 0 | – | Jun 23, 2026 |
| Liam Ratcliffe | Director | – | – | Jun 23, 2026 |
| Donald William Nicholson | Director | 15,332 | 0.04% | Jun 23, 2026 |
| Mona Ashiya | Director | 186,541 | 0.49% | Jun 13, 2025 |
| Genesis GP LLC OrbiMed | Director | 941,569 | 2.45% | Mar 26, 2025 |
| Advisors Llc Orbimed | Director | 5,798,532 | 15.10% | Mar 26, 2025 |
| Capital GP VIII LLC OrbiMed | Director | – | – | Mar 26, 2025 |
| Capital GP VI LLC OrbiMed | Director | 187,297 | 0.49% | Mar 26, 2025 |
| Industries Holdings LLC Access | 10% owner | 3,558,426 | 9.27% | Oct 24, 2025 |
| Dmi Llc Ai | 10% owner | 2,814,379 | 7.33% | Oct 24, 2025 |
| Access Industries Management, Llc | 10% owner | 3,141,759 | 8.18% | Oct 24, 2025 |
| Len Blavatnik | 10% owner | – | – | Oct 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| William Jacob Savage Chief Medical Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −16,035 | $85.09 | $1.36M | 63,445 |
| Kevin Bitterman Director | Oct 21, 2026 | Sale(10b5-1 plan) | −266 | $80.23 | $21.34K | 12,991 |
| Kevin Bitterman Director | Oct 21, 2026 | Sale(10b5-1 plan) | −11,470 | $80.23 | $920.24K | 293,430 |
| Kevin Bitterman Director | Oct 21, 2026 | Sale(10b5-1 plan) | −13,783 | $80.23 | $1.11M | 296,277 |
| Kevin Bitterman Director | Oct 20, 2026 | Sale(10b5-1 plan) | −55 | $79.95 | $4.40K | 13,257 |
| Kevin Bitterman Director | Oct 20, 2026 | Sale(10b5-1 plan) | −2,388 | $79.95 | $190.92K | 304,900 |
| Kevin Bitterman Director | Oct 20, 2026 | Sale(10b5-1 plan) | −2,869 | $79.95 | $229.38K | 310,060 |
| Kevin Bitterman Director | Oct 19, 2026 | Sale(10b5-1 plan) | −115 | $79.97 | $9.20K | 13,312 |
| Kevin Bitterman Director | Oct 19, 2026 | Sale(10b5-1 plan) | −4,942 | $79.97 | $395.21K | 307,288 |
| Kevin Bitterman Director | Oct 19, 2026 | Sale(10b5-1 plan) | −5,937 | $79.97 | $474.78K | 312,929 |
| John D. Quisel Chief Executive Officer, Director | Sep 15, 2026 | Option exercise | +36,000 | $1.01 | $36.36K | 262,064 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +7,136 | $45.69 | $326.04K | 7,136 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +10,000 | $38.85 | $388.50K | 17,136 |
| Kevin Bitterman Director | Sep 11, 2026 | Sale | −27,136 | $70.11 | $1.90M | 0 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +10,000 | $50.86 | $508.60K | 27,136 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −759 | $79.96 | $60.69K | 312,230 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −18 | $79.96 | $1.44K | 13,427 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −912 | $79.96 | $72.92K | 318,866 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −2,339 | $79.98 | $187.07K | 312,989 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −2,810 | $79.98 | $224.74K | 319,778 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −54 | $79.98 | $4.32K | 13,445 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −511 | $80.17 | $40.97K | 13,501 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −2 | $80.98 | $162 | 13,499 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −9 | $80.98 | $729 | 315,328 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −10 | $80.98 | $810 | 322,588 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −22,090 | $80.17 | $1.77M | 315,337 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −26,542 | $80.17 | $2.13M | 322,598 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1 | $79.95 | $80 | 14,012 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −58 | $79.95 | $4.64K | 337,427 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −70 | $79.95 | $5.60K | 349,140 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 25, 2026 | Option exercise | +8,796 | $13.50 | $118.75K | 63,120 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −8,796 | $83.12 | $731.12K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 24, 2026 | Option exercise | +300 | $13.50 | $4.05K | 54,624 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −300 | $82.53 | $24.76K | 54,324 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −8,400 | $78.11 | $656.12K | 250,664 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −11,888 | $79.84 | $949.14K | 226,064 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −12,712 | $79.20 | $1.01M | 237,952 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Option exercise | +33,000 | $13.50 | $445.50K | 259,064 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 12, 2026 | Option exercise | +804 | $13.50 | $10.85K | 55,128 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 12, 2026 | Sale(10b5-1 plan) | −804 | $82.64 | $66.44K | 54,324 |
| Rahul Khara Chief Legal Officer | Aug 6, 2026 | Option exercise | +5,000 | $14.69 | $73.45K | 57,324 |
| Rahul Khara Chief Legal Officer | Aug 6, 2026 | Sale(10b5-1 plan) | −5,000 | $80.00 | $400.00K | 52,324 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −9,704 | $74.27 | $720.72K | 249,360 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Option exercise | +7,416 | $13.50 | $100.12K | 259,064 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Option exercise | +25,584 | $9.86 | $252.26K | 251,648 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −6,400 | $76.05 | $486.72K | 226,064 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −16,896 | $74.95 | $1.27M | 232,464 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −100 | $82.50 | $8.25K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jul 7, 2026 | Option exercise | +100 | $13.50 | $1.35K | 54,424 |
| Rahul Khara Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −1,649 | $75.00 | $123.68K | 52,173 |
| Rahul Khara Chief Legal Officer | Jun 29, 2026 | Option exercise | +1,649 | $14.69 | $24.22K | 53,822 |
| Rahul Khara Chief Legal Officer | Jun 26, 2026 | Option exercise | +851 | $14.69 | $12.50K | 53,024 |
| Rahul Khara Chief Legal Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −851 | $75.00 | $63.83K | 52,173 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −300 | $72.50 | $21.75K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 26, 2026 | Option exercise | +300 | $13.50 | $4.05K | 54,624 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −9,700 | $72.66 | $704.80K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 22, 2026 | Option exercise | +9,700 | $13.50 | $130.95K | 64,024 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −5,400 | $69.94 | $377.68K | 54,273 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −1,600 | $70.73 | $113.17K | 52,673 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −500 | $71.62 | $35.81K | 52,173 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Disc Medicine's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,956 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| William Jacob Savage Officer | Nov 10, 2026 | 16,035 | $1.30M | Nov 10, 2026 | Previously Exercised Options |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Oct 21, 2026 | 11,470 | $911.64K | Oct 21, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Oct 21, 2026 | 13,783 | $1.10M | Oct 21, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Oct 21, 2026 | 33,461 | $2.66M | Oct 21, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Oct 21, 2026 | 266 | $21.14K | Oct 21, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Oct 20, 2026 | 6,965 | $549.75K | Oct 20, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Oct 20, 2026 | 55 | $4.34K | Oct 20, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Oct 20, 2026 | 2,388 | $188.48K | Oct 20, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Oct 20, 2026 | 2,869 | $226.45K | Oct 20, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Oct 19, 2026 | 5,937 | $337.46K | Oct 19, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Oct 19, 2026 | 4,942 | $280.90K | Oct 19, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Oct 19, 2026 | 14,414 | $819.29K | Oct 19, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Oct 19, 2026 | 115 | $6.54K | Oct 19, 2026 | Private Placement |
| Kevin Bitterman Officer | Sep 11, 2026 | 27,136 | $1.90M | Sep 11, 2026 | Exercise of Options Under a Registered Plan |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Sep 4, 2026 | 912 | $72.39K | Sep 4, 2026 | Private Placement |
See a number that looks wrong?